Takeda’s ENTYVIO Nears Pediatric IBD FDA Approval
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 9, 2026 Takeda has reached a significant regulatory milestone with the U.S. Food...
Ulcerative Colitis
Advertisement
Mabwell Receives NMPA Clearance for 9MW5211 in Inflammatory Bowel Disease
SHANGHAI, China, June 5, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug...
Abivax’s Obefazimod Delivers Landmark Phase 3 Success in Ulcerative Colitis
PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...
Johnson & Johnson Wins FDA Label Expansion for TREMFYA
HORSHAM, Pennsylvania, May 28, 2026 Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and...
Abivax Reports Strong Three-Year Remission Results for Obefazimod in Ulcerative Colitis
PARIS, France, May 22, 2026 Abivax announced new three-year interim data from Study 108 showing that obefazimod maintained durable...
Advertisements
Mabwell Wins FDA IND Clearance for 9MW5211 in IBD
SHANGHAI, China – May 8, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that...
AbbVie Showcases IBD Data for Skyrizi and Rinvoq
NORTH CHICAGO, Ill., May 5, 2026 AbbVie Inc. has presented extensive new data across its gastroenterology portfolio at the...
Lilly Omvoh Shows 4-Year UC Disease Clearance Results
INDIANAPOLIS, May 5, 2026 Eli Lilly and Company has reported new long-term clinical data demonstrating that Omvoh® (mirikizumab-mrkz) achieved...
MRM Health Launches Phase 2b UC Trial with MH002
GHENT, Belgium, May 2, 2026 MRM Health announced the initiation of its Phase 2b STARFISH-UC clinical trial (NCT07296315) evaluating...
Cristcot NDA Accepted for ngHCA in Ulcerative Colitis
Austin, Texas, USA, April 21, 2026 In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced...
Advertisement
